



Results are displayed in a computed author sort order. The Publication Date timeline is not available.

- 1 [Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutinin: the effect on in vitro platelet function.](#)
van Wyk V, Leblond L, Winocour PD, Devine DV, Gyongyossy-Issa MI.
Thromb Res. 2000 Aug 15;99(4):343-52. doi: 10.1016/s0049-3848(00)00257-7.
PMID: 10963785
- 2 [Insertion of the Asp-Ser/Phe sequence in the P' position of hirutinin provides molecules having both antithrombin and disintegrin activity.](#)
Leblond L, DiMaio J, Winocour PD.
Thromb Res. 1999 Feb 15;93(4):171-81. doi: 10.1016/s0049-3848(98)00182-0.
PMID: 10064272
- 3 [In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.](#)
Leblond L, Grouix B, Boudreau C, Yang Q, Siddiqui MA, Winocour PD.
Thromb Res. 2000 Nov 1;100(3):195-209. doi: 10.1016/s0049-3848(00)00333-9.
PMID: 11108907
- 4 [BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.](#)
Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD.
Thromb Haemost. 1998 Feb;79(2):431-8.
PMID: 9493603
- 5 [Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.](#)
Bachand B, Tarazi M, St-Denis Y, Edmunds JJ, Winocour PD, Leblond L, Siddiqui MA.
Bioorg Med Chem Lett. 2001 Feb 12;11(3):287-90. doi: 10.1016/s0960-894x(00)00636-3.
PMID: 11212093
- 6 [Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.](#)
St-Denis Y, Augelli-Szafran CE, Bachand B, Berryman KA, DiMaio J, Doherty AM, Edmunds JJ, Leblond L, Lévesque S, Narasimhan LS, Penvose-Yi JR, Rubin JR, Tarazi M, Winocour PD, Siddiqui MA.
Bioorg Med Chem Lett. 1998 Nov 17;8(22):3193-8. doi: 10.1016/s0960-894x(98)00550-2.
PMID: 9873701
- 7 [Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.](#)
Lévesque S, St-Denis Y, Bachand B, Prévile P, Leblond L, Winocour PD, Edmunds JJ, Rubin JR, Siddiqui MA.
Bioorg Med Chem Lett. 2001 Dec 17;11(24):3161-4. doi: 10.1016/s0960-894x(01)00661-8.
PMID: 11720865
- 8 [The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 2.](#)
Cody WL, Augelli-Szafran CE, Berryman KA, Cai C, Doherty AM, Edmunds JJ, He JX, Narasimhan LS, Penvose-Yi J, Plummer JS, Rapundalo ST, Rubin JR, Van Huis CA, Leblond L, Winocour PD, Siddiqui MA.
Bioorg Med Chem Lett. 1999 Sep 6;9(17):2503-8. doi: 10.1016/s0960-894x(99)00419-9.
PMID: 10498197
- 9 [Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors.](#)
St-Denis Y, Lévesque S, Bachand B, Edmunds JJ, Leblond L, Prévile P, Tarazi M, Winocour PD, Siddiqui MA.
Bioorg Med Chem Lett. 2002 Apr 22;12(8):1181-4. doi: 10.1016/s0960-894x(02)00131-2.

10 [A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen.](#)
Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T, Attardo G.
Vascul Pharmacol. 2003 Feb;40(2):77-89. doi: 10.1016/s1537-1891(02)00339-7.
PMID: 12646396

FOLLOW NCBI



Connect with NLM

National Library of Medicine
 8600 Rockville Pike
 Bethesda, MD 20894

Web Policies
 FOIA
 HHS Vulnerability Disclosure

Help
 Accessibility
 Careers

NLM | NIH | HHS | USA.gov